Dapagliflozin: a review on efficacy, clinical effectiveness and safety
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/13543784.2013.740009
Reference30 articles.
1. Islet cell failure in type 2 diabetes
2. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
3. Megatrials in type 2 diabetes. From excitement to frustration?
4. Dapagliflozin: more than just another oral glucose-lowering agent?
5. Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08
2. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety;World Journal of Diabetes;2024-07-15
3. A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date;European Journal of Pharmaceutical Sciences;2023-05
4. Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review);Life;2022-05-27
5. Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus;Mini-Reviews in Medicinal Chemistry;2021-08-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3